TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Enlivex ( (ENLV) ) is now available.
Enlivex Therapeutics Ltd. released its unaudited condensed consolidated financial statements for the periods ending September 30, 2025, and 2024. The financial report highlights a decrease in total assets from $27.7 million at the end of 2024 to $20.9 million by September 2025, alongside a net loss of $7.5 million for the nine months ending September 2025. This financial performance reflects ongoing challenges in the company’s operations, potentially impacting its market position and stakeholder confidence.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.
Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Therapeutics Ltd. is a biotechnology company based in Israel, focusing on the development of innovative immunotherapy treatments. The company is primarily engaged in creating therapies for life-threatening conditions related to the immune system.
Average Trading Volume: 457,703
Technical Sentiment Signal: Sell
Current Market Cap: $24.34M
For detailed information about ENLV stock, go to TipRanks’ Stock Analysis page.